Boston Scientific Corporation vs Vanguard Mega Cap Growth ETF — how do they compare? Boston Scientific Corporation trades at $51.07 (market cap $74.19B), while Vanguard Mega Cap Growth ETF trades at $91.07. The key difference: Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | MGK | |
|---|---|---|
Market Cap | $74.19B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $108.14 | $92.06 |
52-Week Low | $42.63 | $70.70 |
Enterprise Value | $86.27B | — |
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →